POTASSIUM CHLORIDE 0.3% IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating: safe
No significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride (KCl) replaces potassium ions lost from the body and is essential for nerve conduction, muscle contraction, and maintenance of intracellular tonicity. Dextrose provides caloric support, and sodium chloride restores sodium and chloride deficits.
| Metabolism | Potassium is primarily excreted renally; not significantly metabolized. Dextrose is metabolized to carbon dioxide and water via glycolysis and the Krebs cycle. Sodium and chloride are renally regulated. |
| Excretion | Potassium chloride: primarily renal (90% excreted in urine, with minimal fecal loss). Sodium chloride: renal excretion accounts for >95% of eliminated sodium and chloride. Dextrose: completely metabolized to CO2 and water; no significant renal excretion. |
| Half-life | Potassium chloride: not applicable as a single half-life; plasma potassium is tightly regulated. Sodium chloride: no defined half-life; sodium and chloride are distributed and excreted according to homeostasis. Dextrose: rapid, with a half-life of 15-30 minutes for glucose in normal individuals. |
| Protein binding | Potassium: negligible (<1%). Sodium: negligible. Chloride: negligible. Dextrose: not bound. |
| Volume of Distribution | Potassium: approximately 8-10 L/kg (total body water, with most intracellular). Sodium: 0.3-0.5 L/kg (extracellular fluid). Chloride: similar to sodium. Dextrose: initially distributes in extracellular fluid (0.2 L/kg), then enters cells. |
| Bioavailability | Not applicable for intravenous route; 100% bioavailable. |
| Onset of Action | Intravenous: immediate upon infusion, with correction of electrolyte imbalances and dextrose metabolism occurring within minutes. |
| Duration of Action | Duration depends on infusion rate and patient status; for a single dose, effects on potassium last until redistributed or excreted (hours). Continuous infusion needed for sustained effect. |
Intravenous infusion; adult: 1000-2000 mL/day (providing 3 g NaCl, 50 g dextrose, and 30 mEq K+ per 1000 mL) at a rate determined by fluid and electrolyte needs, typically 0.5-1 mEq/kg/hr potassium; not to exceed 10 mEq/hr potassium without continuous cardiac monitoring.
| Dosage form | INJECTABLE |
| Renal impairment | GFR <10 mL/min: use with extreme caution, reduce potassium content, or avoid; monitor serum potassium and ECG. GFR 10-30 mL/min: administer with caution, consider lower potassium concentrations. GFR >30 mL/min: no specific adjustment recommended. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B or C: no specific dose adjustment required, but monitor electrolytes and fluid balance due to potential fluid overload and hepatorenal syndrome. |
| Pediatric use | Infants and children: intravenous infusion based on daily maintenance requirements; typical potassium dose: 1-4 mEq/kg/day, given at a rate not exceeding 0.5-1 mEq/kg/hr; dextrose dose: 5-10 mg/kg/min; sodium dose: 2-3 mEq/kg/day. Use in plastic container as per weight-based fluid calculations. |
| Geriatric use | Use lower end of dosage range; administer slowly at ≤0.5 mEq/kg/hr potassium; monitor renal function, serum electrolytes, and fluid status closely due to age-related renal decline and risk of hyperkalemia or fluid overload. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Breastfeeding | Potassium and chloride are normal milk constituents; dextrose is a normal energy source. M/P ratio not established but expected to be similar to serum. No known adverse effects in breastfed infants. Compatible with breastfeeding. |
| Teratogenic Risk | Potassium chloride and dextrose at standard concentrations are not associated with teratogenicity. However, hyperkalemia can cause fetal arrhythmias. In first trimester, no known teratogenic risk. In second and third trimesters, maternal electrolyte disturbances may affect fetal homeostasis. No human data indicating malformations. |
■ FDA Black Box Warning
Concentrated potassium solutions (including this preparation) must be diluted and administered slowly to avoid fatal hyperkalemia. Do not administer undiluted. Rapid infusion can cause cardiac arrest.
| Common Effects | fluid replacement |
| Serious Effects |
Severe renal impairment with oliguria/anuria, untreated Addison's disease, hyperkalemia, hypoparathyroidism, acute dehydration, heat cramps, hypertonic saline solutions, concomitant use with potassium-sparing diuretics (unless severe hypokalemia).
| Precautions | Risk of hyperkalemia, especially in renal impairment, adrenal insufficiency, or with potassium-sparing diuretics. Monitor serum potassium and ECG. Use with caution in patients with cardiac disease, acidosis, or dehydration. Incompatible with ceftriaxone; do not co-administer. |
Loading safety data…
| Fetal Monitoring | Monitor maternal serum potassium and glucose levels periodically. Monitor for signs of hyperkalemia (ECG changes, muscle weakness). Fetal heart rate monitoring if maternal electrolyte disturbances arise. |
| Fertility Effects | No known effects on fertility. Excipients at standard doses do not impair reproductive function. |